No abstract available.
Urokinase-Type Plasminogen Activator*

Urokinase use after stereotaxic evacuation of hematoma became a popular method in treatment of hypertensive intracerebral hematoma. We obtained excellent result in evacuaIon of the hematoma which was remained after stereotaxic evacuation or direct approach for 24 raumatic intracerebral hematoma cases. And we found several advantages in this method compared with standard treatment modalities. We think that this is a new, effective treatment method for traumatic intracerebral hematoma.
Hematoma* ; Urokinase-Type Plasminogen Activator*

No abstract available.
Empyema* ; Humans* ; Urokinase-Type Plasminogen Activator*

BACKGROUND: Early thrombolysis with intra-arterial urokinase(UK) or intravenous(IV) t-PA may be beneficial for patients with acute ischemic stroke, but this therapy is unavailable in some circumstances and cannot be applied in the cases of late admission. Thus, continuous IV UK infusion has been applied empirically in many hospitals of our country. However, the therapeutic efficacy of this therapy is not known yet. In this study, we investigated the safety and the clinical effect of continuous IV UK infusion. METHOD: 68 patients with acute supratentorial ischemic stroke within 3 days of onset received 6 x 105units of UK daily by continuous infusion for 5 days without loading dose. We estimated European stroke scale (ESS) and Barthel index score (BIS) prior to therapy, on day 1, 3 and 7 after the start of UK, and on the day of discharge. RESULTS: The ESS and BIS were improved in most patients after the therapy. There are no differences in therapeutic effects among the various stroke subtypes and the starting times of therapy after onset. Out of 10 TIA patients, 9 patients did not undergo further TIA and only one patient had complete infarction during UK infusion. Complications were noted in 7(10.3%) patients. But these complications were all minimal. CONCLUSION: As this study was just an open clinical trial, we could not conclude about definite efficacy of continuous IV UK infusion in acute ischemic stroke. However, this therapy might be at least acceptable safe regimen and deserves to be performed in multicenter double-blind controlled trials to clarify the efficacy.
Humans ; Infarction ; Stroke* ; Urokinase-Type Plasminogen Activator*

Since opening of the Yeungnam University Hospital in June 1983 till end of 1984, total 30 cases of cerebral thrombosis were analyzed clinically. Among the 30. 17 cases were given Urokinase from 60,000 to 240,000 units daily for 2-46 days. The interval from the onset to the inititiation of therapy varied from 1 hour to 17 days. Ten cases showed marked recovery and 6 cases moderate improvement. One case, in which only 120,000 units daily were administered, showed stationary course. The interval of the Urokinase untreated 13 cases was from 3 days to 18 months. Six cases were sationary, whereas 7 cases showed mild improvement. Age, sex, past history, associated diseases, and the laboratory findings are shown in the tables. Conclusion is that the earlier the therapy started, the higher the dosage used, the better of the results is obtained.
Intracranial Thrombosis* ; Urokinase-Type Plasminogen Activator*

No abstract available.
Intestine, Small ; Ischemia ; Urokinase-Type Plasminogen Activator

No abstract available.
Thrombolytic Therapy ; Urokinase-Type Plasminogen Activator

Percutaneous drainage of liver abscess is an effective treatment, but the success rate is low for liver abscess that has septa and is multilocular. We experienced one case of successful treatment of multilocular liver abscess using administration of Urokinase into an abscess cavity during the course of percutaneous drainage.
Abscess ; Catheters* ; Drainage* ; Liver Abscess* ; Liver* ; Urokinase-Type Plasminogen Activator*

We had tried to perform mechanical aspiration using Hematoma and fibrinolytic drainage with Urokinase for treatment of spontaneous intracerebral hematoma(SICH) in 24 patients. Mean initial volume of SICH was 53.65+/-26.34 ml, mean evacuated amount of SICH after Hematoma procedure was 46.25+/-23.64%, and mean evacuated amount of SICH after fibrinolytic drainage after Urokinase was 74.15+/-20.89%, compared with pre-operative status. We could aspirate more than 50% of hematoma if the Hematoma procedure had been performed within 18 hours after ictus(p=0.0306). The rebleeding rate after Hematoma procedure was 8.3%, and overall mortality rate was 12.5%. There results seem to indicate mechanical aspiration using Hematoma and fibrinolytic drainage with Urokinase might be one of the useful method for treatment of SICH.
Drainage ; Hematoma* ; Humans ; Mortality ; Suction ; Urokinase-Type Plasminogen Activator*

The best treatment modality of spontaneous intracerebral hematoma is still controversial. But stereotactic surgery can minimize the brain damage and be performed under local anesthesia. Recently we experienced 46 cases of spontaneous intracerebral hematoma which were operated using ZD(Zamorano-Dujovny) stereotactic system and urokinase irrigation from November 1990 to April 1993. Before operation, computerized tomographic scanning was done to locate the hematoma, assess the amount, and to determine the stereotactic coordinates. The silastic tube was inserted after stereotactic evacuation of hematoma and urokinase irrigation was repeated every 6 to 8 hours until the hematoma was cleared up. The results were analysed and we concluded that we can substitute open craniectomy or conservative treatment for stereotactic evacuation of spontaneous intracerebral hematoma combined with urokinase irrigation in certain instances and can minimize the brain damage regardless the patient's general condition or past history.
Anesthesia, Local ; Brain ; Cerebral Hemorrhage* ; Hematoma ; Urokinase-Type Plasminogen Activator*